Doximity Authorizes New $500M Buyback, Settles Lawsuit, Reports Mixed Q3 FY26 Results

summarizeSummary

Doximity announced mixed Q3 FY26 results with 10% revenue growth but an 18.1% net income decline, alongside authorizing a new $500 million stock repurchase program and settling a $31 million securities lawsuit fully covered by insurance.

check_boxKey Events

• New $500M Stock Repurchase Program Authorized

  The Board of Directors authorized an additional $500 million Class A common stock repurchase program on February 3, 2026, following the near-exhaustion of a previous $500 million program. This represents a substantial capital return initiative.

• Mixed Q3 FY26 Financial Performance

  Revenue increased 10% year-over-year to $185.1 million, but net income decreased 18.1% to $61.6 million, and diluted EPS fell to $0.31 from $0.37. Adjusted EBITDA, however, grew by 9.2%.

• Securities Lawsuit Settled for $31M

  The company settled a securities lawsuit for $31 million on December 24, 2025. The cost is fully covered by insurance, resolving a significant legal overhang without material financial impact to the company.

• Strategic AI Acquisition Completed

  Doximity completed the acquisition of Pathway Medical Inc., an AI-based medical knowledge platform, on July 29, 2025, for $36.3 million, aiming to enhance its technology and workforce.

auto_awesomeAnalysis

This 10-Q filing provides comprehensive financial and operational details for Q3 FY26, following the concurrent 8-K earnings announcement. The most significant new development is the authorization of a new $500 million stock repurchase program, signaling strong management confidence and a commitment to shareholder returns, especially as the stock trades near its 52-week lows. The settlement of a major securities lawsuit for $31 million, fully covered by insurance, removes a significant legal overhang. While revenue grew by 10% year-over-year, the 18.1% decline in net income for the quarter is a notable concern. The company also detailed its recent acquisition of AI-based Pathway Medical, Inc., a strategic move for platform enhancement. Investors should monitor the impact of the buyback on share price and the progress of the remaining legal proceedings.